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Abstract 
The relative toxicity of anxiolytic and hypnotic drugs commonly used for self-poisoning 
was assessed using data on suicides, prescriptions and non-fatal self-poisonings in 
England, 2005-2012. Data on suicide by self-poisoning were obtained from the Office 
for National Statistics (ONS), information on intentional non-fatal self-poisoning was 
derived from the Multicentre Study of Self-harm in England and data on prescriptions in 
general practice from the Clinical Practice Research Datalink (CPRD). We used two 
indices of relative toxicity: fatal-toxicity (the number of fatal self-poisonings relative to 
the number of individuals prescribed each drug) and case-fatality (the number of fatal 
relative to non-fatal self-poisonings). Diazepam was the reference drug in all analyses. 
Temazepam was 10 times (95% CI 5.48-18.99) and zopiclone/zolpidem nine times 
(95% CI 5.01-16.65) more toxic in overdose than diazepam (fatal-toxicity index). 
Temazepam and zopiclone/zolpidem were 13 (95% CI 6.97-24.41) and 12 (95% CI 
6.62-22.17) times more toxic than diazepam, respectively (case-fatality index). 
Differences in alcohol involvement between the drugs were unlikely to account for the 
findings. Overdoses of temezepam and zopiclone/zolpidem are considerably more 
likely to result in death than overdoses of diazepam. Practitioners need to exercise 
caution when prescribing these drugs, especially for individuals who may be at risk of 
self-harm, and also consider non-pharmacological options.  
Keyword: minor tranquilizers, sedatives, relative toxicity, suicide, self-harm, self-
poisoning   
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Introduction 
Minor tranquilizers (anxiolytics) and hypnotic drugs are used extensively for the 
treatment of various psychological problems, including anxiety disorders and 
insomnia.(Alessi-Severini et al., 2014) According to data from the NHS Business 
Services, over 16 million prescriptions for minor tranquilizers and hypnotics were 
written and dispensed in England in 2013, benzodiazepines accounting for 58% of 
these and ‘Z-drugs’ (i.e. zopiclone, zaleplon, and zolpidem) accounting for 39%.(The 
National Institute for Health and Care Excellence (NICE), 2016) Self-poisoning is a 
common method of self-harm. Data from the Multicentre Study of Self-harm in England 
show that 79% of all presentations to emergency departments following self-harm are 
due to self-poisoning, and 14% of these involve benzodiazepines/hypnotics.(Geulayov 
et al., 2016) Insomnia and psychiatric disorders including anxiety are common in 
patients who self-harm (Perlis et al., 2016; Hysing et al., 2015; Hawton et al., 2013; 
Khan et al., 2002) so that many individuals at risk for self-harm are in receipt of these 
medications.  
Data on the relative toxicity of individual benzodiazepines/hypnotic medications are 
sparse, but some differences in toxicity have been reported within the class of 
benzodiazepines. Buckley and co-investigators, for example, found that temazepam 
had a greater sedative effect relative to other benzodiazepines when consumed in 
overdose.(Buckley et al., 1995) Reith et al. reported similar toxic risk for zopiclone to 
that of benzodiazepines as a group, (Reith et al., 2003) although their study was very 
small, including only 12 zopiclone-related deaths. Given the widespread use of 
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anxiolytic and hypnotic medications and their significant involvement in acts of self-
poisoning, together with the scarcity of published research in this area, there is a need 
for further investigation of their relative safety.  
In this study we focussed on the anxiolytic and hypnotic drugs diazepam, temazepam, 
chlordiazepoxide, lorazepam, nitrazepam, and zopiclone because they are commonly 
used for both fatal and non-fatal self-poisoning in the UK. Data from the Office for 
National Statistics, for example, show that benzodiazepines and Z-drugs (zopiclone 
and zolpidem) were involved in 14% of deaths due to self-poisoning (including both 
suicides and accidental deaths) in England and Wales in 2012 (diazepam and 
zopiclone/zolpidem accounted for in 79% of those), (Office for National Statistics, 2014) 
similar to their involvement in non-fatal hospital presentations for self-
poisoning.(Geulayov et al., 2016) The benzodiazepines/hypnotics investigated in the 
present study were also the most widely prescribed in the community in England as 
highlighted in a report by NHS Digital. (NHS Digital, 2015)  
Our overall aim was to provide information on relative toxicity of these drugs which may 
assist clinicians in making decisions about prescribing and contribute to policy advice 
of regulatory agencies. We used two indices of relative toxicity. 1) Fatal-toxicity: for 
each drug we calculated the number of self-poisoning deaths relative to the number of  
individuals prescribed this drug). 2) Case-fatality: the number of self-poisoning deaths 
relative to the number of episodes of non-fatal self-poisoning involving this drug). We 
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also examined the extent of alcohol involvement in fatal self-poisoning as concerns 
have been raised about the interactions of these drugs with alcohol. (Koski et al., 2002)  
Methods  
In this analysis of data on suicides, prescriptions and non-fatal self-poisonings in 
England (2005-2012), we investigated the relative toxicity of the following 
benzodiazepine/sedative medications: diazepam, temazepam, chlordiazepoxide, 
lorazepam, nitrazepam, and zopiclone and zolpidem. The ‘Z-drugs’ were grouped into 
a single group of ‘zopiclone/zolpidem’, in keeping with data from the Clinical Practice 
Research Datalink. Data on prescriptions as provided by CPRD did not differentiate 
between the Z-drugs because only 1% of the prescriptions were for zolpidem. The 
remaining were for zopiclone. This led to our decision to merge zopiclone and zolpidem 
into a single category in all analyses. Data from ONS and from the Multicentre Study of 
Self-harm in England, in which ‘Z-drugs’ are recorded separately, showed that the vast 
majority of events involving these drugs (86% and 93%, respectively) were due to the 
ingestion of zopiclone, a figure consistent with data from the NHS Business Services 
Authority.(NHS Business Services Authority 2012)  
Data used in this study were for the eight complete years 2005 to 2012. We obtained 
data separately by gender and by single year of age.  
 
Data sources 
Deaths. Information on deaths due to self-poisoning with benzodiazepine/hypnotic 
medications was provided by the Office for National Statistics (ONS) based on deaths 
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registrations in England occurring during 2005-2012 which were registered by the end 
of 2013 (location was assigned using postcode of usual residence based on the 
November 2013 National Statistics Postcode Directory). Deaths receiving a verdict of 
intentional self-poisoning or death of undetermined intent (open verdict) that involved 
the study benzodiazepines/sedative medications were included. Open verdicts were 
included in accordance with current policy on suicide statistics and research in the UK, 
on the basis that the majority are possible suicides.(Linsley et al., 2001; Office for 
National Statistics, 2015; Gunnell et al., 2013) Deaths by accidental self-poisoning 
were excluded. Therefore, the term ‘suicide’ in this paper includes intentional self-
poisoning together with open verdicts.  
 
Non-fatal self-poisoning. Information on non-fatal self-harm by self-poisoning was 
obtained from the Multicentre Study of Self-harm in England. The study is described in 
detail elsewhere.(Hawton et al., 2007) It involves data collection on all presentations for 
self-harm to the emergency departments at five general hospitals in Oxford (one 
hospital), Manchester (three hospitals) and Derby (two hospitals that merged into one 
in 2009). Self-harm is defined as intentional self-poisoning or self-injury, irrespective of 
the motivation or degree of suicidal intent.(Hawton et al., 2003a) Self-poisoning with 
drugs includes the intentional ingestion of more than the prescribed amount of any 
drug, whether or not there is evidence that the act was intended to result in death. Data 
were collected on gender, age, date and method of self-poisoning, including the 
specific drugs ingested. Data were extracted for all episodes of non-fatal self-poisoning 
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involving individuals aged 15 years and over which included the study 
benzodiazepine/hypnotic medication, regardless of whether or not other drugs or 
alcohol were involved. Only episodes by individuals who (at the time of the self-harm 
episodes) resided in the catchment area of Oxford City, Manchester City and Derby 
Unitary area were included in the analysis because reliable mid-year population 
estimates, which are required to calculate rates, were available for these areas. 
Prescription of medications. Data on benzodiazepine/hypnotic medications dispensed 
in the community in England were obtained from the Clinical Practice Research 
Datalink (CPRD).(The Clinical Practice Research Datalink (CPRD), 2016) The CPRD is 
a governmental research service which provides anonymised primary care records for 
research. It currently contains data on approximately 10% of the UK population. 
Information from the CPRD included the number of patients registered with the general 
practices appearing in the CPRD database and the number of individuals who were 
prescribed a specific study medication, by year (2005-2012), age and gender. 
 
Measures of toxicity 
 
We used two indices of relative toxicity. 
Fatal toxicity. For each benzodiazepine/sedative drug we calculated the number of 
deaths by self-poisoning in England during 2005-2012 attributed to this drug divided by 
the number of individuals prescribed this drug during the equivalent period and 
standardised these to the risk for diazepam to derive the fatal toxicity index. 
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Case fatality. The number of deaths by self-poisoning in England during 2005-2012 
attributed to a given drug divided by the number of episodes of non-fatal self-poisoning 
involving this drug during the equivalent period from the Multicentre Study of Self-harm 
in England and standardised these to the risk for diazepam to derive the case-fatality 
index. 
 
Diazepam was chosen as the reference drug because it is the most widely prescribed 
benzodiazepine in the UK(The Clinical Practice Research Datalink (CPRD), 2016) and 
is most commonly used for self-poisoning.(Camidge et al., 2003)  
 
Alcohol involvement 
Information on the presence of alcohol in cases of fatal self-poisoning was obtained 
from ONS records and was based on the coroners’ toxicology reports. 
 
Ethical approval 
The monitoring systems for self-harm in Oxford and Derby have approval from local 
Health/Psychiatric Research Ethics Committees to collect data on self-harm for local 
and multicentre projects. Self-harm monitoring in Manchester is part of a clinical audit 
system, and has been ratified by the local Research Ethics Committee. All three 
monitoring systems are fully compliant with the Data Protection Act (1998). All centres 
have approval under Section 251 of the National Health Services (NHS) Act (2006) to 
collect patient identifiable information without explicit patient consent.  
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We obtained specific Independent Scientific Advisory Committee (ISAC) approval from 
the CPRD (protocol number 14_064R2) and from ONS to obtain mortality data. The 
approved protocol was made available to the journal reviewers at the time of 
submission. 
 
Statistical analysis 
We calculated rates of suicide by self-poisoning per 100,000 person-years using 
England’s mid-year population estimates for 2005-2012 obtained from the Office for 
National Statistics. (Office for National Statistics, 2016) Rates of non-fatal self-
poisoning were based on the number of episodes of non-fatal self-poisoning per 
100,000 person-years using mid-year population estimates obtained from ONS (Office 
for National Statistics, 2016) for 2005-2012 for the geographical areas covered by the 
Multicentre Study of Self-harm (Oxford City, the City of Manchester, and Derby Unitary 
area). Prescription rates were calculated as the number of individuals prescribed a 
specific medication per 100,000 person-years registered with the general practices in 
the CPRD during 2005-2012. The analyses were carried out using the Poisson 
distribution with exact 95% CIs. 
Relative toxicity of specific drugs was calculated by computing ratios of the number of 
deaths involving each drug to the total number of individuals prescribed the specific 
drugs (fatal-toxicity) or to the total number of episodes of non-fatal self-poisoning with 
each drug (case-fatality). Confidence intervals for relative toxicity were calculated using 
the Poisson distribution. (Hawton et al., 2003b)  
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We conducted two sets of analyses for each of the toxicity indices used in this study 
(fatal toxicity and case fatality). First, we included only deaths involving single drugs 
(with or without alcohol). Second, we also included cases of suicides involving multiple 
drugs where the drug of interest was the first drug recorded by the coroner. We did this 
on the basis that the first recorded drug was likely to be the main cause of death.  
In a further analysis we differentiated between zopiclone and zolpidem and calculated 
separate case-fatality index (suicide to non-fatal self-poisoning). This was possible 
because data on suicides and non-fata self-poisoning were recorded separately for 
zopiclone and zolpidem.  
We ran the analyses by gender and examined the proportion of alcohol involvement in 
fatal self-poisoning in each of the medications studied. Analysis by age was not 
possible due to small numbers. 
Statistical analysis was carried out using Stata 14.1.  
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Results 
Fatal toxicity 
During 2005-2012, there were 179 suicides (~22 suicides per year) due to self-
poisoning involving a benzodiazepine/hypnotic drug where the benzodiazepine/hypnotic 
drug was the only self-poisoning agent. There were an additional 109 suicide deaths 
(~14 per year) where the benzodiazepine/hypnotic was consumed with other 
medications but was listed as the first self-poisoning agent (i.e. 288 in total). During this 
period approximately 5% of individuals aged 15 years and over included in the CPRD 
were prescribed at least one of the study benzodiazepines/hypnotics annually. 
 
The prescription data showed that diazepam was the most prescribed 
benzodiazepine/hypnotic, followed by zopiclone/zolpidem, while chlordiazepoxide was 
the least prescribed medication of the drugs under investigation (Table 1). The highest 
numbers of suicide deaths during the study period were recorded for 
zopiclone/zolpidem, followed by temazepam, while lorazepam was implicated in the 
fewest deaths (Table 1). 
Findings for the relative toxicity of the individual benzodiazepine/hypnotic drugs as 
measured by the fatal toxicity index (suicide deaths relative to individuals prescribed 
each drug) where the drug under investigation was the only self-poisoning agent 
recorded (Table 2) showed that temazepam was the most toxic drug i.e. over ten-fold 
more toxic than the reference drug, diazepam [odds ratio (OR) 10.20, 95% confidence 
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intervals (CI) 5.48 to 18.99). Similarly, zopiclone/zolpidem were over nine-fold more 
toxic than diazepam (OR 9.14, 95% CI 5.01 to 16.65). Nitrazepam and 
chlordiazepoxide were over six times more toxic than diazepam (OR 6.65, 95% CI 2.14 
to 20.62; OR 6.28, 95% CI 2.47 to 15.96, respectively). While the relative toxicity 
indices for temazepam, chlordiazepoxide and nitrazepam were higher for females than 
for males, the overlap between CIs suggest weak evidence for gender differences (this 
was not formally tested). 
In a second set of analyses we estimated fatal toxicity including also deaths in which 
the drug under investigation appeared with other medication but was listed as the first 
drug (Table 2). The findings appeared smaller in magnitude, showing that temazepam 
and zopiclone/zolpidem were approximately five times more toxic than diazepam while 
nitrazepam was almost three times more toxic than diazepam, but the evidence for 
greater toxicity of chlordiazepoxide was weak. It is worth noting that the majority of 
fatal-poisonings involving temazepam (72%), chlordiazepoxide (100%), nitrazepam 
(78%) and zopiclone (62%) were reported as single drug self-poisonings, while this 
was the case for 34% and 40% of fatal self-poisonings involving diazepam and 
lorazepam, respectively. 
 
Case fatality 
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During 2005-2012 there were on average 576 non-fatal self-poisoning presentations a 
year involving benzodiazepine/sedative drugs to the emergency departments in the 
general hospitals in the three centres participating in the Multicentre Study of Self-harm 
in England by individuals residing in the catchment areas of the three study sites (Table 
3). Diazepam was the most common drug used in these episodes, followed by 
zopiclone/zolpidem, while nitrazepam was the least common of the drugs under 
investigation.  
 
Consistent with our findings from the fatal toxicity analysis, using the case fatality index 
(suicide deaths to non-fatal self-poisoning episodes) the relative toxicity of individual 
drugs where the drug under investigation was the only agent recorded in the fatal 
poisonings showed that temazepam and zopiclone/zolpidem were 13-and 12-fold more 
toxic than the reference drug diazepam, respectively (OR 13.04, 95% CI 6.97 to 24.41; 
OR 12.12, 95% CI 6.62 to 22.17, respectively) (Table 4). Furthermore, the relative 
toxicity estimates were markedly larger for nitrazepam and chlordiazepoxide relative to 
diazepam (OR 6.28, 95% CI 2.44 to 16.14; OR 3.27, 95% CI 1.05 to 10.24, 
respectively), while the toxicity of lorazepam was comparable to that of diazepam. 
There was some indication that toxicity of all the drugs other than zopiclone/zolpidem 
may be greater in females than males, although this was not formally tested. 
There were similar findings when fatal toxicity was calculated by including single and 
first-drug listed suicides (Table 4), although the effect estimates were markedly smaller. 
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Nitrazepam was almost three times more toxic than diazepam but there was weak 
evidence for greater toxicity of chlordiazepoxide in this analysis. 
A direct comparison between temazepam and zopiclone/zolpidem showed no evidence 
of a difference between the two hypnotic drugs. This finding was consistent across 
indices of relative toxicity and in the analysis using single as well as poly-drug self-
poisoning. 
In a further analysis we separated zolpidem and zopiclone fatal and non-fatal self-
poisonings. Using the single drug suicides only, the analysis showed that ingesting 
zolpidem was 20.6 times more likely to result in death relative to diazepam (OR 20.6, 
95% CI 8.86-48.01) while ingesting zopiclone was 11.5 times more likely to result in 
death than diazepam (OR 11.50, 95% CI 6.23-21.14). A direct comparison between 
zolpidem and zopiclone indicated that zolpidem was associated with a 1.8 increased 
toxicity relative to zopiclone but this was consistent with chance (OR 1.80, 95% CI 
0.92-3.48). Including also multiple drugs fatal self-poisonings showed that zolpidem 
was 13.5 times more toxic than diazepam (OR 13.50, 95% CI 7.55-24.16) while 
zopiclone was 6.2 times more toxic than diazepam (OR 6.17, 95% CI 4.22-9.01). A 
direct comparison between zolpidem and zopiclone indicated that zolpidem was 2.2 
more likely to result in death relative to zopiclone (OR 2.19, 95% CI 1.32-3.64). 
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Alcohol involvement 
There were some variations in the proportion of individuals for whom alcohol was 
reported by coroners as being present in their blood after death by self-poisoning. 
Focussing on the drugs involved in at least ten single-drug deaths this was 20.7% 
(12/58) for temazepam, 33.3% (4/12) for diazepam and 37.6% (36/96) for 
zopiclone/zolpidem. For deaths involving single or multiple drugs (where the drug of 
interest was the first listed drug), the proportion of individuals for whom the presence of 
alcohol was recorded were very similar to those found for single drug deaths.  
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Discussion 
 
We have investigated the relative toxicity of benzodiazepine and hypnotic drugs 
commonly used for self-poisoning. Using two methods to calculate relative toxicity of 
individual benzodiazepine/hypnotic medications, there was consistent evidence that 
overdoses of temezepam and zopiclone/zolpidm are considerably more likely to result 
in death than overdoses of diazepam. A more inclusive approach, including deaths 
involving single and multiple drugs, led to the same conclusion. Chlordiazepoxide and 
nitrazepam were approximately six times more toxic than diazepam but inclusion of 
multiple drug suicides attenuated these differences, although nitrazepam remained 
somewhat more toxic than diazepam. Temazepam, chlordiazepoxide and nitrazepam 
appeared to be more toxic in females than males, although no formal gender 
comparisons were conducted due to small numbers.  
The increased risk of fatal self-poisoning attributed to temazepam and 
zopiclone/zolpidem, and to a lesser extent nitrazepam, may suggest that these 
medications are inherently more toxic than other minor tranquilizers/hypnotics and 
therefore lead to more deaths when taken in overdose. Alternatively, differences 
between the patient groups prescribed these drugs may account for the observed 
differences. For example, individuals who suffer from insomnia (and who are mostly 
treated pharmacologically with zopiclone/zolpidem or temazepam) are also at a greater 
risk of death by suicide.(Perlis et al., 2016; Hysing et al., 2015; Bjorngaard et al., 2011) 
Similarly, chlordiapoxide, is often prescribed for the management of withdrawal 
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symptoms in alcohol dependence, although chlordiapoxide was among the least toxic 
drugs in this analysis. Furthermore, there may be differences in therapeutic doses 
required to treat insomnia and those required to alleviate symptoms of anxiety (by e.g. 
diazepam, lorazepam) which may, in turn, lead to a difference in access to a potentially 
lethal dose - a risk factor for completed suicide.(Hawton, 2007) Other factors which 
may have contributed to the observed differences in lethality may have been related to 
differences in the dose ingested and to the co-ingestion of alcohol or other substances 
(see limitations below).  
Buckley and colleagues (Buckley et al., 1995) also showed heightened toxicity, as 
indexed by greater sedation, for temazepam in overdose relative to other 
benzodiazepines in patients who self-poisoned, independently of age, gender, dose 
ingested, and co-ingestion of alcohol. The authors, however, did not investigate fatal 
poisoning and did not include zopiclone or zolpidem in their analysis. Similarly, 
temazepam was found to have the second highest fatal-toxicity index (including 
suicides and deaths by accidental self-poisoning), after flurazepam, among hypnotic 
and anxiolytic medications examined in a UK-based study.(Serfaty and Masterton, 
1993) This finding is in keeping with that of Buckley and McManus’s study in which 
temazepam was ranked 3rd highest among other sedatives/hypnotics evaluated in 
terms of deaths per number of prescriptions, although zopiclone and zolpidem were 
ranked among the least toxic in this study and even less so relative to diazepam. 
(Buckley and McManus, 2004) Nevertheless, in a Norwegian study the investigators 
compared the risk of fatal and non-fatal acute poisoning, including suicides and 
18 
 
accidental deaths, associated with zopiclone and benzodiazepines. Their findings 
showed that zopiclone was approximately four times more toxic than other 
benzodiazepines.(Bjornaas et al., 2010) However, benzodiazepines were analysed as 
a single group, precluding direct comparison with our results. Furthermore, a review by 
the World Health Organization has highlighted the frequent involvement of sedative 
hypnotics including nitrazepam and zopiclone in suicides by self-poisoning.(World 
Health Organization (WHO), 2006)  
Some pharmacological properties of diazepam, temazepam and zopiclone should also 
be considered. These drugs are rapidly absorbed so a differential onset of action for 
pharmacokinetic does not seem a likely explanation. As noted above, temazepam 
seems to produce more sedation in overdose than other benzodiazepines (Buckley et 
al., 1995) and  in animal studies both the affinity of temazepam for central 
benzodiazepine receptors and its speed to occupy them greater than that of diazepam. 
(Muller and Stillbauer, 1983) Despite this, clinical conversion tables often suggest that 
temazepam is less potent than diazepam (Alexander and Perry, 1991) which raises the 
possibility that in clinical use temazepam is dosed relatively more heavily than 
diazepam. Another factor that might be relevant is that diazepam, unlike zopiclone and 
temazepam, is metabolised to a long-acting metabolite desmethyldiazepam. In animal 
studies, desmethyldiazepam has lesser potency than diazepam at the central 
benzodiazepine receptor and, indeed, has been suggested to act as a partial agonist at 
this site. (Gobbi et al., 1987) This raises the possibility that during overdose, 
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conversion of diazepam to the less potent desmethydiazepam might be relatively 
protective against the toxicity of the parent compound.  
Both temazepam and zopiclone have been popular as hypnotic agents because their 
relatively short duration of action is believed to lessen the extent of daytime 'hangover' 
effects. Data from the CPRD show that zopiclone is the second and temazepam the 
third most commonly prescribed of the study drugs after diazepam. Also, prescribing of 
‘Z-drugs’ in England increased by 33% (38% increase for zopiclone) between July 
2005 and September 2010. (NHS Business Services Authority 2012) Our finding that 
zopiclone/zolpidem and temazepam when taken in overdose are associated with a 
markedly greater risk of death than the other study drugs, coupled with the finding that 
individuals who suffer from insomnia are at a greater risk of self-harm and 
suicide,(Perlis et al., 2016; Hysing et al., 2015; Bjorngaard et al., 2011) highlight the 
need for further evaluation of the safety profile for these drugs and the importance of 
increasing the availability of non-pharmacological treatments, such as advice on 
good sleep hygiene and cognitive behavioural therapy (CBT), (Siebern et al., 2012) 
which have been shown to be effective, and even superior to medications, in managing 
insomnia, especially in the long term.(Mitchell et al., 2012) Use of CBT as a first-line 
treatment for insomnia was included in the National Institute for Health and Care 
Excellence (NICE) guidance to the NHS over a decade ago.(National Institute for 
Health and Care Excellence (NICE), 2004) It was further concluded that there had 
been no compelling evidence of a difference between the Z-drugs and short-acting 
benzodiazepines in terms of effectiveness, adverse effects, or potential for misuse or 
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dependence,(Gibson, 2004; National Institute for Health and Care Excellence (NICE), 
2004) although the fact that short-acting benzodiazepines are associated with next-day 
residual effects cannot be overlooked. 
 Strengths and weaknesses 
A major strength of this study is the large sample size and the fact that we included 
eight years of data and the use of two approaches to assessing toxicity, both 
converging on the same conclusion. However, some limitations should be considered. 
The data sources in this investigation are not linked, so the indices are based on 
largely different populations. Information on prescriptions of medications were obtained 
from the CPRD which includes data on approximately 7% of the population actively 
registered with one of 674 participating practices across the UK although CPRD 
patients are broadly representative of the UK population in terms of age, sex and 
ethnicity. (Herrett et al., 2015) Another potential source of prescribing data would be 
national sources (https://digital.nhs.uk/catalogue/PUB23631). However, these data are 
for overall numbers of prescriptions rather than individuals and are not provided by 
gender. Crude comparisons of findings for fatal-toxicity based on these data indicate 
that they would be similar to those in our study, with particularly high toxicity of 
temazepam and the Z-drugs.  Information on non-fatal self-poisonings were based on 
the Multicentre Study of Self-harm in England, which involves all presentations to five 
general hospitals in Oxford, Manchester and Derby. These three centres include a 
socioeconomically diverse population. On the basis of the Index of Multiple Deprivation 
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2007 for England,(Department for Communities and Local Government, 2008) which 
combines information from several domains including income, employment, education, 
skills and training, health and disability, crime, barriers to housing and Services, and 
living environment, Manchester was ranked the fourth most deprived local authority in 
England, Derby was ranked 69th and Oxford 155th. Furthermore, the consistency in 
findings using the fatal-toxicity and the case-fatality approaches increases confidence 
in the results. 
 Furthermore, we were unable to distinguish between the different ‘Z-drugs’ in our 
analyses of fatal toxicity as ‘Z-drugs’ in the CPRD (prescriptions) data were merged 
into a single category of zopiclone/zolpidem although we were able to calculate case-
fatality separately for zopiclone and zolpidem since data from ONS and from the 
Multicentre Study of Self-harm differentiated between these drugs. 
Our primary analyses are based on single-agent indices of toxicity. Although this 
method can provide greater certainty about the agent which caused death, multiple 
drugs are involved in many cases. We have carried out further analyses of multiple 
drugs used in fatal self-poisoning, the results of which were in keeping with the results 
of the primary analysis. Notably, the majority of fatal poisonings involving the drugs 
deemed more toxic in this study were single drug self-poisoning deaths: temazepam 
(72%), nitrazepam (78%) and zopiclone/zolpidem (62%), compared to 34% and 40% of 
deaths involving diazepam and lorazepam, respectively. We did not account for the 
amount of medication consumed in overdose as data provided by the ONS do not 
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include this information. Another question is whether fatal self-poisoning is related to 
greater involvement of alcohol or of other medications. Concerns have been raised 
about the safety of benzodiazepines/hypnotics in combination with alcohol, which may 
lead to respiratory failure.(Koski et al., 2002) Our examination of alcohol involvement in 
fatal self-poisoning suggests that there might be some differences in the proportion of 
alcohol involvement in the different drugs, but these differences are not likely to 
account for the observed findings. For example, the proportion of individuals who had 
alcohol reported in combination with temazepam was lower than the proportion of 
individuals who had alcohol reported in combination with diazepam while the proportion 
of individuals who had alcohol reported in combination with zopiclone/zolpidem was 
slightly higher than that reported for diazepam. However, data on alcohol involvement 
in suicide deaths may be incomplete as the accuracy of Coroner’s reports on presence 
of alcohol is uncertain. Nevertheless, in toxicological examination of 204 persons who 
died by suicide in the US, alcohol was recorded in 35% of toxicology reports for 
individuals who tested positive for hypnotics,(Mendelson and Rich, 1993) although this 
study might also have been subjected to under-recording of alcohol involvement.  
A further point which merits discussion is the inclusion of open verdicts as suicides. As 
stated above, we included deaths by self-poisonings which received a suicide or open 
verdict codes by the coroners, in accordance with current policy on suicide statistics 
and research in the UK. (Office for National Statistics, 2015) The proportions of 
individuals whose deaths received an open verdict were 33.9% (single drug deaths) 
and 37.4% (single or multiple drugs deaths). Previous research suggest some 
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inconsistencies between research-defined and coroner defined open verdict 
classifications as suicides, although temporal and area variations have also been 
reported. (Linsley et al., 2001; Gunnell et al., 2013) This may be a limitation of the 
present data although we have no reason to believe that the level of misclassification is 
different between the drugs under investigation.   
Lastly, the extent to which individuals who self-poisoned with zopiclone/zolpidem and 
temazepam had used medication prescribed for them or drugs obtained through other 
means is unclear. It has been reported, for example, that people who obtain zopiclone 
through unregulated sources tend to consume larger quantities of the drugs and in 
combination with other substances than those using prescribed 
medication.(Newcombe, 2009) 
 
Conclusion and policy implications 
The CPRD data indicate that during 2005-2012, approximately 250,000 individuals 
were prescribed the study benzodiazepines/hypnotics by a general practitioner each 
year. Extrapolating to the population of England, this is equivalent to approximately 2.5 
million individuals aged 15 years and over each year.  
Earlier concerns about the health risks associated with prolonged use of 
benzodiazepines/hypnotic drugs (Weich et al., 2014) stimulated legislative changes to 
prescription-writing requirements in the UK,(British National Formulary (BNF), 2017; 
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British National Formulary (BNF), 2014) and also storage and recording requirements 
in Australia. (The Goverment of Western Australia - Department of Health, 2013)  
However, the findings of the present investigation, together with those of other studies 
highlighted above, suggest that temazepam and zopiclone/zolpidem may be 
associated with a substantially greater risk of death in persons who self-poison. 
Therefore, policymakers and practitioners may need to consider the apparent 
differential risks of these drugs, especially as they are the two most commonly 
prescribed hypnotics (at least in the UK). Furthermore, given the potential impairment 
in functioning and distress associated with insomnia and in the absence of safer drug 
alternatives, there is a need for greater focus on psychological management of 
sleeping problems, especially when dealing with vulnerable patients. Further studies 
which include reliable recording of multiple-drug involvement and alcohol in fatal and 
non-fatal self-poisoning as well as information about doses ingested are required in 
order to confirm our findings.  
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Table 1. The number and rates of suicides involving single-drugs or single and multiple 
(first-listed) drugs in England and the number and rate of individuals prescribed each of 
the medications (from the Clinical Practice Research Datalink), in individuals aged 15 
years and over (2005–2012)  
 Fatal self-poisoning in England (2005-12) Prescriptions (2005-12) 
 Single drug Single drug and first 
drug listed 
 Total 
N 
Death rate per 
100,000 person-
years  
(95% CI) 
Total 
N 
Death rate per 
100,000  
person-years 
(95% CI) 
Average 
Number 
per year 
Prescription rate 
per 100,000 
person-years 
(95% CI) 
Diazepam 12  0.0035  
(0.0018-0.0061) 
35 0.0102 
(0.0071-0.0142) 
89,930 1946.08 
(1941.59-1950.59) 
Temazepam 58 0.0170  
(0.0129-0.0219) 
81 0.0236 
(0.0188-0.0294) 
42,629 922.49 
(919.40-925.59) 
Chlordiazepoxide 4 0.0012 
(0.0003-0.0030) 
4 0.0012 
(0.0003-0.0030) 
4,508 97.56 
(96.55-98.57) 
Lorazepam 2 0.0006 
(0.00007-0.0021) 
5 0.0015 
(0.0005-0.0034) 
10,678 231.06 
(229.52-232.62) 
Nitrazepam 7 0.0021 
(0.0008-0.0004) 
9 0.0026 
(0.0012-0.0050) 
8,351 180.72 
(179.36-182.10) 
Zopiclone/ 
zolpidem 
96 0.0281 
(0.0227-0.0343) 
154 0.0450 
(0.0382-0.0527) 
78,750 1704.17 
(1699.96-1708.38) 
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 Fatal self-poisoning in England (2005-12) Prescriptions (2005-12) 
 Single drug Single drug and first 
drug listed 
 Total 
N 
Death rate per 
100,000 person-
years  
(95% CI) 
Total 
N 
Death rate per 
100,000  
person-years 
(95% CI) 
Average 
Number 
per year 
Prescription rate 
per 100,000 
person-years 
(95% CI) 
 
All drugs  179  288  234,846  
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Table S1. The number of suicides in England in individuals aged 15 years (2005–
2012), the number of individuals in the CPRD prescribed each of the study 
benzodiazepines/hypnotics and death rate per million persons prescribed these 
medications  
 Total 
number of 
suicides  
(2005-2012) 
Total N of individuals 
prescribed the drug 
(2005-2012) 
Deaths per million individuals 
prescribed the drug  
(95% CI) 
Single drug 
Diazepam 12  719,436 16.7 (8.62-29.1) 
Temazepam 58 341,030 170.1 (129.1-219.9) 
Chlordiazepoxide 4 36,066 110.9 (30.2-284.0) 
Lorazepam 2 85,420 23.4 (2.84-84.6) 
Nitrazepam 7 66,811 104.8 (42.1-215.9) 
Zopiclone/zolpidem 96 630,003 152.4 (123.4-186.1) 
All drugs  179 1,878,766  
Single drug and first drug listed 
Diazepam 35 719,436 48.6 (33.9-67.7) 
Temazepam 81 341,030 237.5 (188.6-295.2) 
Chlordiazepoxide 4 36,066 110.9 (30.2-284.0) 
Lorazepam 5 85,420 58.5 (19.0-136.6) 
Nitrazepam 9 66,811 134.7 (61.6-255.7) 
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Zopiclone/zolpidem 154 630,003 244.4 (207.4-286.2) 
All drugs  288 1,878,766  
 
  
31 
 
Table 2. Fatal toxicity index – the number of suicides involving a given drug per 
individuals prescribed this drug relative to diazepam: single-drug only and single or first 
listed drug, by gender 
 Odds ratio (95% CI) 
 Both genders Males Females 
 
Single drug suicides only 
Diazepam Reference Reference Reference 
Temazepam 10.20 (5.48 to 18.99) 7.81 (3.39 to 17.99) 13.53 (5.27 to 34.71) 
Chlordiazepoxide 6.65 (2.14 to 20.62) 3.78 (0.79 to 18.19) 10.89 (2.11 to 56.13) 
Lorazepam 1.40 (0.31 to 6.27) 1.17 (0.14 to 9.53) 1.71 (0.20 to 14.62) 
Nitrazepam 6.28 (2.47 to 15.96) 3.55 (0.74 to 17.09) 10.06 (2.91 to 34.76) 
Zopiclone/zolpidem 9.14 (5.01 to 16.65) 9.71 (4.45 to 21.18) 7.61 (2.97 to 19.53) 
 
Single drug and first listed drug suicides 
Diazepam Reference Reference Reference 
Temazepam 4.88 (3.28 to 7.26) 3.20 (1.89 to 5.42) 8.10 (4.29 to 15.29) 
Chlordiazepoxide 2.28 (0.81 to 6.42) 1.15 (0.27 to 4.88) 4.54 (1.02 to 20.28) 
Lorazepam 1.20 (0.47 to 3.07) 0.36 (0.05 to 2.64) 2.85 (0.92 to 8.83) 
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 Odds ratio (95% CI) 
 Both genders Males Females 
 
Single drug suicides only 
Nitrazepam 2.77 (1.33 to 5.76) 1.62 (0.49 to 5.40) 5.03 (1.89 to 13.41) 
Zopiclone/zolpidem 5.03 (3.48 to 7.25) 4.80 (3.06 to 7.54) 4.96 (2.63 to 9.30) 
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Table 3. The number and rate of suicides involving single-drugs or single and multiple 
(first-listed) drugs in England and the number and rates of non-fatal self-poisoning 
episodes in three centres in England, in individuals aged 15 years and over (2005–
2012)  
 Fatal self-poisoning in England (2005-12) Non-fatal self-poisoning 
in the 3 centres (2005-12)  Single drug Single drug and first 
listed drug  
 Total 
N 
Death rate per 
100,000 person-
years  
(95% CI) 
Total 
N 
Death rate per 
100,000  
person-years 
(95% CI) 
Average 
Number 
per year 
Prescription 
rate per 
100,000 
person-years 
(95% CI) 
Diazepam 12 0.0035  
(0.0018-0.0061) 
35 0.0102 
(0.0071-0.0142) 
250 34.92 
(33.41-36.48) 
Temazepam 58 0.0170  
(0.0129-0.0219) 
81 0.0236 
(0.0188-0.0294) 
93 12.94 
(12.03-13.91) 
Chlordiazepoxide 4 0.0012 
(0.0003-0.0030) 
4 0.0012 
(0.0003-0.0030) 
26 3.56 
(3.09-4.08) 
Lorazepam 2 0.0006 
(0.00007-0.0021) 
5 0.0015 
(0.0005-0.0034) 
30 4.19 
(3.67-4.75) 
Nitrazepam 7 0.0021 
(0.0008-0.0004) 
9 0.0026 
(0.0012-0.0050) 
23 3.24 
(2.79-3.75) 
Zopiclone/zolpidem 96 0.0281 154 0.0450 165 23.06 
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 Fatal self-poisoning in England (2005-12) Non-fatal self-poisoning 
in the 3 centres (2005-12)  Single drug Single drug and first 
listed drug  
 Total 
N 
Death rate per 
100,000 person-
years  
(95% CI) 
Total 
N 
Death rate per 
100,000  
person-years 
(95% CI) 
Average 
Number 
per year 
Prescription 
rate per 
100,000 
person-years 
(95% CI) 
(0.0227-0.0343) (0.0382-0.0527) 
 
(21.83-24.34) 
All drugs 179  288  576  
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Table 4. Case fatality – the number of suicides involving a given drug per non-fatal 
self-poisoning episode relative to diazepam: single-drug only and single or first listed 
drug, by gender 
 Odds ratio 
(95% CI)  
 Both genders Males Females 
 
Single drug suicides only 
Diazepam Reference Reference Reference 
Temazepam 13.04 (6.97 to 24.41) 10.50 (4.51 to 24.44) 16.73 (6.48 to 43.20) 
Chlordiazepoxide 3.27 (1.05 to 10.24) 2.16 (0.44 to 10.52) 4.98 (0.95 to 26.03) 
Lorazepam 1.39 (0.31 to 6.25) 1.41 (0.17 to 11.63) 1.50 (0.17 to 12.93) 
Nitrazepam 6.28 (2.44 to 16.14) 3.01 (0.61 to 14.71) 10.94 (3.11 to 38.40) 
Zopiclone/zolpidem 12.12 (6.62 to 22.17) 14.93 (6.79 to 32.82) 9.22 (3.58 to 23.76) 
 
Single drug and first listed drug suicides 
Diazepam Reference Reference Reference 
Temazepam 6.24 (4.16 to 9.37) 4.30 (2.50 to 7.40) 10.02 (5.29 to 19.09) 
Chlordiazepoxide 1.12 (0.40 to 3.19) 0.66 (0.15 to 2.85) 2.08 (0.46 to 9.41) 
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 Odds ratio 
(95% CI)  
 Both genders Males Females 
 
Single drug suicides only 
Lorazepam 1.19 (0.46 to 3.07) 0.43 (0.06 to 3.23) 2.50 (0.80 to 7.85) 
Nitrazepam 2.77 (1.31 to 5.85) 1.37 (0.40 to 4.67) 5.47 (2.01 to 14.87) 
Zopiclone/zolpidem 6.67 (4.59 to 9.68) 7.38 (4.64 to 11.75) 6.00 (3.18 to 11.34) 
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